KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to $8.5 billion.

  • Cvs Health's Cash & Equivalents fell 154.9% to $8.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.5 billion, marking a year-over-year decrease of 154.9%. This contributed to the annual value of $8.5 billion for FY2025, which is 154.9% down from last year.
  • Cvs Health's Cash & Equivalents amounted to $8.5 billion in Q4 2025, which was down 154.9% from $9.1 billion recorded in Q3 2025.
  • In the past 5 years, Cvs Health's Cash & Equivalents registered a high of $17.2 billion during Q3 2022, and its lowest value of $5.6 billion during Q1 2021.
  • Its 5-year average for Cash & Equivalents is $10.5 billion, with a median of $9.8 billion in 2021.
  • As far as peak fluctuations go, Cvs Health's Cash & Equivalents plummeted by 5212.19% in 2021, and later surged by 7501.53% in 2022.
  • Quarter analysis of 5 years shows Cvs Health's Cash & Equivalents stood at $9.4 billion in 2021, then surged by 37.6% to $12.9 billion in 2022, then tumbled by 36.69% to $8.2 billion in 2023, then rose by 4.76% to $8.6 billion in 2024, then dropped by 1.55% to $8.5 billion in 2025.
  • Its Cash & Equivalents stands at $8.5 billion for Q4 2025, versus $9.1 billion for Q3 2025 and $11.8 billion for Q2 2025.